





Progress achieved in 2007

- 2007 a year of transition and focus, covered by Annual Report and AGM

 this presentation looks at 2008 and beyond
- Group now operating in two clear business areas of:

BioPlastics RF Applications

- Strategy and direction for both areas developed and being enacted and refined
- Highly capable and experienced management in both business areas
- Remain well funded with substantial cash resources



business operations



Sales by Business

	ZIII	
	2007	2006
Bioplastics RF Applications Other	6.8 1.1 0.2	5.4 1.1 0.2
Total	8.1	6.7



RF Applications

- The RF activity re-focused on mobile welders, fibre optics furnaces, zirconia tubes and parts/servicing
- Expectations originally placed on *GreenSeal* food lidding technology exceeded commercial practicality further work terminated
- Stanelco's brand is strong, customers welcoming re-engagement
- New product pipeline in place initial developments are now being industrialised (portable welder/stepper welder)
- Enquiry levels (optical fibre furnace market) have increased (Asian focus)
- Scope to re-build an OEM engineering business



BioPlastics Introduction

- Stanelco BioPlastics has begun to position itself as leader in the bio-plastics market
- Stanelco BioPlastics is formed of:

Business Area	Activities
Aquasol (UK)	Patent portfolio of product/packaging designs based around water soluble materials.
Biotec (Germany)	Bioplastic production and development facility (50/50) ownership
BioPlastics Team (UK/Europe)	Commercial team trialling & selling bioplastic materials. UK based technical support and development facilities



Bioplastics Market

- Global bioplastics market is exciting and with various technology types competing for an emerging applications
- Europe: focus on compostable/biodegradable other markets require sustainable (oil-replacement) products
- Huge enquiry/trial loads as various customers assess their appetite for the differing properties/costs/values associated with biomaterials.
 Commercial applicability proven in some areas
- Technical properties of bioplastics often fall short of the oil-based equivalents in functionally demanding applications – Stanelco is closing this gap



BioPlastics - Aquasol

- Board review (supported by PwC report) identified areas of potential value
- Limited development activity will focus on a few key products, particularly where synergies exist with bioplastic materials
- Existing royalty streams will be managed and other routes to deliver value from patents will be sought
- FrogMat is being developed with a credible commercial partner
 - A first semi-commercial pilot line has been built and commissioned
 - Market testing currently underway



BioPlastics - Biotec

- Biotec founded in 1991 now has 17 years of experience developing biobased materials
- Base product range is market leading alongside other bioplastics but is still limited functionally vs. some oil based equivalents
- Investment during the early part of the year increased capacity significantly (now capable of operating 24/7 running)
- 26% sales increase at BioPlastics in 2007 (48% increase on pro-rata basis) - yet to test current capacity
- Novamont claim of patent infringement has provided some drag to sales growth – Stanelco/Biotec mounting vigorous defence of noninfringement/invalidity



BioPlastics - Stanelco

- Stanelco is drawing together a strong commercial/technical team to drive commercialisation & development
- Paul Law joined in October as MD with 20 year background in biomaterials – sales focus galvanised and producing result
- Stanelco now has direct control of product optimisation with pilot/development line in UK
- Technical product support and rapid development is key as customers explore materials
- Focus on functional materials with bio credentials, end-use markets are widening



outlook



Outlook

RF Applications

 enquiry levels are robust – work continues in product innovation and sales development

BioPlastics

- market interest in Stanelco products is vigorous with initial indications of broader product acceptance
- UK pilot/development facilities have been commissioned and have a full work programme for 2008 – new product functionality focus
- business has begun to explore accelerating commercialisation through different routes to market



Outlook

- Stanelco is re-focused and re-invigorated
- Clear priority of achieving growth through commercialisation of technology and products – structures in place to do this through direct sales, partnerships and other innovative routes
- The Stanelco BioPlastic business is accelerating in this emergent and highly visible/relevant market
- Stanelco is building a market leading position and has the market lead/IP depth to drive rapid and defensible growth
- Stanelco has substantive cash resources and we are looking for innovative routes to roll-out the bioplastic technology at an accelerated rate
- The current year has started well and we expect continued good progress. This gives the Board confidence in the outlook for further development in 2008



